<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32029967</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1998-3751</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Indian journal of pharmacology</Title><ISOAbbreviation>Indian J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Novel therapeutic targets for amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>418</StartPage><EndPage>425</EndPage><MedlinePgn>418-425</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/ijp.IJP_823_19</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an untreatable and fatal neurodegenerative disease that is identified by the loss of motor neurons in the spinal cord, brain stem, and motor cortex which theatrically reduces life expectancy. Although the primary cause of ALS remains unclear, its heterogeneity put forward for consideration of association with various factors, including endogenous and/or environmental ones, which may be involved in progressive motor neuron stress that causes activation of different cell death pathways. It is hypothesized that this disease is triggered by factors related to genetic, environmental, and age-dependent risk. In spite of large neurobiological, molecular and genetic research, at the beginning of the 21<sup>st</sup> century, ALS still remains one of the most devastating neurodegenerative diseases because of the lack of effective therapeutic targets. It is a challenge for the clinical and scientific community. A better understanding of the etiology of ALS is necessary to develop specific targets of this progressive neurodegenerative disease. This review states about the current knowledge of targets in ALS research. This review provides an overview of the contribution of different targets like mitochondrial dysfunction, glutamate transport and excitotoxicity, protein accumulation, Oxidative stress, neuromuscular junction, microglia, and other molecular targets in the pathogenesis of ALS.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2020 Indian Journal of Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Batra</LastName><ForeName>Gitika</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Manav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Rahul Soloman</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Amit Raj</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Ashutosh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prakash</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medhi</LastName><ForeName>Bikash</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Pharmacol</MedlineTA><NlmUniqueID>7902477</NlmUniqueID><ISSNLinking>0253-7613</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">mitochondrial dysfunction</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">neuronal cell death</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32029967</ArticleId><ArticleId IdType="pmc">PMC6984016</ArticleId><ArticleId IdType="doi">10.4103/ijp.IJP_823_19</ArticleId><ArticleId IdType="pii">IJPharm-51-418</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu H, Le WD, Xie YY, Wang XP. Current therapy of drugs in amyotrophic lateral sclerosis. Curr Neuropharmacol. 2016;14:314&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876587</ArticleId><ArticleId IdType="pubmed">26786249</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash RP, Babu RJ, Srinivas NR. Two decades-long journey from riluzole to edaravone: Revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics. Clin Pharmacokinet. 2018;57:1385&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">29682695</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr Opin Neurol. 2019;32:771&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourie-Devi M, Rao VN, Prakashi R. Neuroepidemiological study in semi urban and rural areas in South India: Pattern of neurological disorders including motor neurone disease. In: Gourie-Devi M, editor. Motor Neuron Disease: Global Clinical Patterns and International Research. New Delhi: Oxford &amp; IBH; 1987. pp. 11&#x2013;21.</Citation></Reference><Reference><Citation>Hancock SM, Iftekhar NT, Jampana SC, Khan M, Mahmud N, Navaneetham D, et al.  Rare diseases and disorders: Research, Resource and Repository for South Asia.  [Last accessed 15 Oct 2019, 6:30 pm].  Available from: http://www.rarediseasesindia.org/als .</Citation></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry. 2005;76:1046&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739758</ArticleId><ArticleId IdType="pubmed">16024877</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: Cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;31:635&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Couratier P, Julian A, Vallat JM, Corcia P, Le Masson G. Management and therapeutic perspectives in amyotrophic lateral sclerosis. Expert Rev Neurother. 2017;17:263&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">27644548</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for ALS (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012;14:CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a ML, Fern&#xe1;ndez A, Solas MT. Mitochondria, motor neurons and aging. J Neurol Sci. 2013;330:18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">23628465</ArticleId></ArticleIdList></Reference><Reference><Citation>Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: Implications for the role of mitochondria in neuronal cell death. Ann Neurol. 1999;46:787&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">10553999</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: The nuedexta treatment trial. Neurotherapeutics. 2017;14:762&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordet T, Buisson B, Michaud M, Drouot C, Gal&#xe9;a P, Delaage P, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2007;322:709&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17496168</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunyach C, Michaud M, Arnoux T, Bernard-Marissal N, Aebischer J, Latyszenok V, et al. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology. 2012;62:2346&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">22369784</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, Fancelli D, Wong M, Niedzwiecki M, Ballarini M, Plyte S, et al. GNX-4728, a novel small molecule drug inhibitor of mitochondrial permeability transition, is therapeutic in a mouse model of amyotrophic lateral sclerosis. Front Cell Neurosci. 2014;8:433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4271619</ArticleId><ArticleId IdType="pubmed">25565966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono Y, Tanaka H, Takata M, Nagahara Y, Noda Y, Tsuruma K, et al. SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models. Neurosci Lett. 2014;559:174&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24334165</ArticleId></ArticleIdList></Reference><Reference><Citation>Foran E, Trotti D. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal. 2009;11:1587&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842587</ArticleId><ArticleId IdType="pubmed">19413484</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, et al. Aberrant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998;20:589&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539131</ArticleId></ArticleIdList></Reference><Reference><Citation>King AE, Woodhouse A, Kirkcaldie MT, Vickers JC. Excitotoxicity in ALS: Overstimulation, or overreaction? Exp Neurol. 2016;275(Pt 1):162&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">26584004</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30:379&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4002277</ArticleId><ArticleId IdType="pubmed">19343058</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch L, Vandenberghe W, Klaassen H, Van Houtte E, Robberecht W. Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci. 2000;180:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11090861</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona JC, Tapia R. AMPA receptor activation, but not the accumulation of endogenous extracellular glutamate, induces paralysis and motor neuron death in rat spinal cord in vivo. J Neurochem. 2004;89:988&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15140197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH, Jr, Johnson H, Qureshi M, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61:456&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939417</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15635412</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizzardo M, Nardini M, Ronchi D, Salani S, Donadoni C, Fortunato F, et al. Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms. Exp Neurol. 2011;229:214&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">21295027</ArticleId></ArticleIdList></Reference><Reference><Citation>Siciliano G, Carlesi C, Pasquali L, Piazza S, Pietracupa S, Fornai F, et al. Clinical trials for neuroprotection in ALS. CNS Neurol Disord Drug Targets. 2010;9:305&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">20406180</ArticleId></ArticleIdList></Reference><Reference><Citation>Paizs M, Tortarolo M, Bendotti C, Engelhardt JI, Sikl&#xf3;s L. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph Lateral Scler. 2011;12:340&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3231880</ArticleId><ArticleId IdType="pubmed">21623665</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:266&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">19961264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Kim WY, Jeon YJ, Lee SK, Son CG. Aquilariae lignum extract attenuates glutamate-induced neuroexcitotoxicity in HT22 hippocampal cells. Biomed Pharmacother. 2018;106:1031&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30119168</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:777&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012;124:339&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">22903397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B, Novoselov S, Gray A, Cheetham ME, Margulis B, Greensmith L. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem. 2008;107:339&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">18673445</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbacher JK, Tabet R, Yeo GW, Lagier-Tourenne C. Disruption of RNA metabolism in neurological diseases and emerging therapeutic interventions. Neuron. 2019;102:294&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545120</ArticleId><ArticleId IdType="pubmed">30998900</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: Emerging roles in RNA processing and neurodegeneration. Hum Mol Genet. 2010;19:R46&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi D, Comi GP, Bresolin N, Corti S. MicroRNAs as regulators of cell death mechanisms in amyotrophic lateral sclerosis. J Cell Mol Med. 2019;23:1647&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378226</ArticleId><ArticleId IdType="pubmed">30614179</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Birsa N, Tosolini AP, Schiavo G. Travelling together: A unifying pathomechanism for ALS. Trends Neurosci. 2020;43:1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">31744630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A, Nakano I, Kurland LT, Mulder DW, Holley PW, Saccomanno G. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1984;43:471&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">6540800</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol Dis. 2017;105:283&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536153</ArticleId><ArticleId IdType="pubmed">28235672</ArticleId></ArticleIdList></Reference><Reference><Citation>Taes I, Timmers M, Hersmus N, Bento-Abreu A, Van Den Bosch L, Van Damme P, et al. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum Mol Genet. 2013;22:1783&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">23364049</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Liu J, She H. Targeting macrophage for the treatment of amyotrophic lateral sclerosis. CNS Neurol Disord Drug Targets. 2019;18:366&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">30963986</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Ravits J. Pathogenic mechanisms and therapy development for C9orf72 amyotrophic lateral sclerosis/frontotemporal dementia. Neurotherapeutics. 2019:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985338</ArticleId><ArticleId IdType="pubmed">31667754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Chen M, Jiang J. Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. Mitochondrion. 2019;49:35&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">31288090</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehgal SA, Hammad MA, Tahir RA, Akram HN, Ahmad F. Current therapeutic molecules and targets in neurodegenerative diseases based on in silico drug design. Curr Neuropharmacol. 2018;16:649&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080102</ArticleId><ArticleId IdType="pubmed">29542412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore E, Casola I, Dobrowolny G, Musar&#xf2; A. Neuromuscular Junction as an Entity of Nerve-Muscle Communication. Cells. 2019;8:pii: E906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6721719</ArticleId><ArticleId IdType="pubmed">31426366</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47:S233&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">8959995</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz MP. Edaravone (Radicava): A novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P T. 2018;43:25&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5737249</ArticleId><ArticleId IdType="pubmed">29290672</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>